Blue Origin and HIV Vaccine

Grind for August 5th
“The worst enemy to creativity is self-doubt.” – Sylvia Plath

To Infinity And Beyond

The Headline

Jeff Bezos sells $1.8 billion worth of stock to fund space venture

The Grind

Amazon CEO Jeff Bezos on Wednesday sold roughly 960,000 of his Amazon shares – each worth about $1,900 – after the company reported weaker-than-expected quarterly earnings.

Despite the sale, Bezos remains the world’s richest person with an estimated net worth of $117 billion.

Bezos typically sells about $1 billion in stocks each year to fund his space company, Blue Origin. He plans to sell even more this year as Blue Origin moves closer to its first commercial flight.

The Details

Blue Origin in May completed its 11th successful test launch of its space tourism rocket, New Shepard. Ideally, Blue Origin will start selling tickets for New Shepard launches later this year.

Blue Origin is competing directly with space tourism company Virgin Galactic, which has already sold 600 tickets for spaceflights scheduled to take place by the end of the year.

In the future, Bezos hopes to use Blue Origin to construct massive orbital structures capable of sustaining colonies of humans.

Medical News

The Headline

HIV vaccine “Mosaico” reaches third phase of clinical trial

The Grind

Thousands of people in the US and Europe next month will participate in a trial to test the effectiveness of a new HIV vaccine.

The vaccine, called “Mosaico,” is a combination of a disabled cold virus and synthetic HIV genes created using strains of HIV from around the world.

As reported in Nature News, Mosaico is expected to boost participants’ resistance to HIV for up to two years.

The Details

Early trials of the vaccine spurred an immune response against HIV, but scientists are still trying to figure out if Mosaico provides any protection against HIV infection.

The upcoming trial includes nearly 4,000 gay and transgender participants from eight countries. Half of the participants will receive Mosaico and half will receive a placebo.

Researchers expect the vaccine to boost HIV resistance in at least 65% of participants who receive the drug.

Results of the massive study are expected to be published in 2023.

Did you know… The microwave was invented after a researcher walked by a radar tube and a chocolate bar melted in his pocket.